Zinostatinstimalamer

Description

Zinostatin stimalamer is a new antineoplastic polymeric agent launched in Japan for the treatment of hepatoma. It was synthesized by chemical conjugation of the synthetic inert poty(styrene-maleic acid) (SMA) and neocarzinostatin (NCS), which is a proteinaceous antitumor agent produced by Streptomyces carzinostaticus. SMANCS not only retains the properties of NCS for inhibiting DNA synthesis in the cell by direct DNA strand scission, but also is able to uniquely augment the host defense system by inducing interferon γ and activating macrophages. Compared with NCS, SMANCS has greatly improved in vitro and in vivo stability, is more effective in reducing tumor size and in preventing the development of new tumors, has decreased toxic side effects and extended plasma half life. In clinical trials, tumor size reductions have been obtained in 90% of patients with hepatoma and dose of 0.7 mg/m² induced complete or almost complete necrosis of tumor without affecting noncancerous liver tissue or the gallbladder.

Originator

Yamanouchi (Japan)

The Uses of Zinostatinstimalamer

Antineoplastic.

brand name

SMANCS